ThyPRO: Skala Hasil yang Dilaporkan Pasien Terkait Tiroid
- Diperkenalkan oleh
- Torquil Watt, Jens Bjørner, Marianne Groenvold
- Tahun
- 2009
- Jenis
- Patient self-report questionnaire
- Keluarga
- Endocrine-specific quality of life
Teks ini adalah terjemahan mesin dan belum ditinjau. Baca versi asli dalam bahasa Inggris
Apa fungsinya?
ThyPRO adalah ukuran hasil yang dilaporkan pasien yang komprehensif yang menilai dampak kualitas hidup dari penyakit tiroid dan pengobatannya di 13 dimensi.
Dikembangkan oleh Watt dan rekan pada tahun 2009, ini adalah instrumen spesifik tiroid yang paling tervalidasi secara ekstensif, mencakup domain fisik dan psikologis yang relevan bagi pasien dengan hipertiroidisme, hipotiroidisme, dan kanker tiroid.
Intuisi di balik metode
Penyakit tiroid secara substansial memengaruhi kualitas hidup di luar kontrol gejala sederhana. ThyPRO menangkap beban multidimensional ini—mulai dari gejala fisik (kelelahan, fluktuasi berat badan, sensitivitas suhu) hingga efek psikologis (kecemasan, kesulitan kognitif, gangguan suasana hati) dan fungsi sosial. Berbeda dengan alat kualitas hidup generik, alat ini mencerminkan apa yang paling penting bagi pasien tiroid dan dokter yang mengelola perawatan jangka panjang mereka. Skala ini mengakui bahwa pengobatan optimal melampaui target biokimia untuk mencakup kesejahteraan yang dilaporkan pasien.
Sejarah
Developed 2009 by Watt, Groenvold, Bjørner and Danish collaborators at University of Copenhagen. Published in J Clin Endocrinol Metab 94(9):3572-3580 (2009). Initial validation included 2,000+ thyroid patients across Graves' disease, Hashimoto thyroiditis, and thyroid cancer populations. Short form (ThyPRO-39) developed 2012 via Rasch analysis; validation completed 2012-2016. Recognized by the American Thyroid Association; adopted in major clinical trials (TAPAS, REACT). Translated into 20+ languages with cross-cultural validation. Continues to evolve with item banking and computerized adaptive testing (CAT-ThyPRO) under development.
Kapan digunakan
ThyPRO is indicated for: (1) Monitoring quality of life in patients with Graves' disease, hashimoto thyroiditis, or thyroid cancer during treatment; (2) Research evaluating interventions for thyroid disease (thyroidectomy, radioiodine, antithyroid drugs); (3) Shared decision-making when balancing treatment intensity vs. quality of life burden; (4) Identifying patients with persistent symptom burden despite biochemical euthyroidism; (5) Evaluating long-term hypothyroid or hyperthyroid symptom persistence. Appropriate for adults aged 18+; pediatric versions under development. Used internationally in clinical trials and increasingly in routine endocrinology practice.
Batasan dan pertimbangan
- 4-week recall period may miss acute symptom fluctuations in patients with rapid mood or energy changes.
- Limited data comparing responsiveness across treatment modalities (surgical, radioiodine, pharmacological) in head-to-head prospective studies.
- Psychological domains (anxiety, irritability) show moderate-high overlap; factor structure remains under refinement in some language versions.
- Ceiling effects observed in some domains among patients with mild disease or well-controlled symptoms; may limit sensitivity in quiescent populations.
Syarat dari sumber tidak menggantikan tinjauan ilmiah independen atau validasi oleh mesin analisis.
Kelebihan
- Multidimensional coverage: 13 distinct domains capture the full symptom and functional burden of thyroid disease, not collapsible to a single dimension.
- Strong psychometric evidence: Extensively validated across multiple languages and patient populations; high internal consistency (Cronbach alpha 0.80-0.95 per domain) and test-retest reliability.
- Responsiveness to clinical change: Sensitive to symptom improvement with treatment; published MCID values enable clinically meaningful difference detection in trials and practice.
- Thyroid-specific content: Developed with patient input to reflect thyroid disease-relevant concerns (e.g., cold/heat intolerance, eye symptoms in Graves' disease), missing from generic QoL measures.
Penerapan
- Clinical trials: Primary or secondary endpoint in hypothyroidism, hyperthyroidism, and thyroid cancer treatment trials evaluating symptom burden reduction.
- Routine endocrinology practice: Baseline and periodic monitoring of patients post-thyroidectomy or radioiodine to assess quality of life trajectory and guide levothyroxine dose adjustments.
- Shared decision-making: Quantifying quality of life trade-offs when counseling patients on surgical vs. medical management or intensity of TSH suppression in thyroid cancer.
- Research epidemiology: Population surveys investigating prevalence of long-term thyroid-related morbidity and predictors of persistent symptoms despite biochemical euthyroidism.
- Comorbidity assessment: Distinguishing thyroid-related symptoms from depression, anxiety disorders, or somatic symptom disorder in patients with multiple diagnoses.
Cara kerjanya
Cara kerjanya
ThyPRO-85 terdiri dari 85 item dengan periode penarikan 4 minggu; ThyPRO-39 adalah bentuk pendek yang tervalidasi dengan 39 item. Item dinilai pada skala Likert (biasanya 4 poin: 'tidak sama sekali' hingga 'sangat'). Responden menilai frekuensi atau tingkat gangguan gejala dan dampak. Waktu administrasi: 10-15 menit (bentuk pendek) hingga 20-25 menit (versi lengkap). Diberikan sendiri melalui alat tulis-kertas atau elektronik; administrasi oleh pewawancara dapat diterima. Membutuhkan kemampuan membaca dan memahami pada tingkat dewasa.
Rumus
Complete all items; no time limit; self-administered or interview-administered
Respons item mentah (0-3 atau 1-4) dikonversi ke skala 0-100 untuk setiap dari 13 domain: (1) Gejala hipertiroid, (2) Gejala hipotiroid, (3) Kelelahan/Fatigue, (4) Gangguan kognitif, (5) Kecemasan, (6) Iritabilitas/Ketidaksabaran, (7) Labilitas emosional, (8) Kenaikan berat badan, (9) Intoleransi dingin, (10) Intoleransi panas, (11) Gejala mata, (12) Gejala kulit, (13) Gejala gondok. Skor domain diperoleh dengan merata-ratakan item yang relevan dan mengubahnya menjadi 0-100. Tidak ada skor komposit total; interpretasi berfokus pada domain individu. Skor yang lebih tinggi = kualitas hidup yang lebih buruk di domain tersebut.
Rumus
Convert raw responses to 0-100 scale per domain; calculate domain means
Skor pada setiap skala domain 0-100 diinterpretasikan sebagai: 0-20 = dampak minimal, 21-40 = dampak ringan, 41-60 = dampak sedang, 61-80 = dampak berat, 81-100 = dampak sangat berat. Perbedaan Klinis Penting Minimal (MCID) biasanya berkisar 8-15 poin tergantung domain. Responsivitas terhadap perubahan pengobatan: ThyPRO menunjukkan sensitivitas yang baik terhadap perbaikan dengan terapi. Profil domain komparatif mengungkapkan gugus gejala yang dominan (misalnya, pola hipotiroid vs. hipertiroid). Digunakan untuk memantau hasil longitudinal dalam uji klinis dan manajemen pasien individu.
Rumus
Higher scores indicate worse quality of life; evaluate domains individually and overall pattern
Kesalahan umum
- Confusing higher scores with better outcomes: ThyPRO is reverse-scored (0-100 with 100 = worst), unlike some other scales. Always verify direction before interpreting.
- Using total score: ThyPRO-85 and ThyPRO-39 do not yield a single summary score. Clinicians unfamiliar with the instrument sometimes attempt to average across domains, losing specificity of symptom domains.
- Assuming score stability across TSH ranges: Symptom improvement lags biochemical correction; thyroid antibody status, comorbidities, and psychological factors independently affect domain scores beyond TSH alone.
Pertanyaan yang sering diajukan
Is ThyPRO-39 as reliable as ThyPRO-85?
Yes. The short form (ThyPRO-39) retains excellent psychometric properties (Cronbach alpha >0.80 per domain) with minimal loss of information compared to the full 85-item version. ThyPRO-39 is recommended for routine clinical use due to shorter administration time (10 minutes vs. 20 minutes) without sacrificing measurement validity.
What TSH target corresponds to best ThyPRO scores?
No fixed TSH threshold predicts ThyPRO response. Patients show wide variation: some achieve good quality of life at TSH 1-2 mIU/L, others report persistent fatigue and cognitive symptoms despite TSH in target range. Individual titration based on both TSH and ThyPRO domains is recommended, particularly for patients with residual hypothyroid complaints at standard TSH targets.
Can ThyPRO be used before diagnosis (screening)?
No. ThyPRO is designed for diagnosed thyroid disease patients and assesses disease-related quality of life. It is not a screening tool for thyroid dysfunction. Use TSH and thyroid antibodies for diagnostic screening.
Are there normative data for comparison to general population?
Yes. Published reference values from >2,000 Danish thyroid patients show mean domain scores by diagnosis (Graves', Hashimoto, post-thyroidectomy). General population comparisons available in peer-reviewed literature; most thyroid populations score 40-60 (moderate impact) on fatigue and emotional domains at baseline.
Metode terkait
Sumber
Watt, T., Bjorner, J. B., Groenvold, M., et al. (2009). Establishing construct validity for the thyroid-related patient reported outcomes (ThyPRO): An initial examination. J Clin Endocrinol Metab, 94(9), 3572-3580.
Buka referensi publikasiDisalin.Watt, T., Groenvold, M., Bjorner, J. B., et al. (2012). Validity and responsiveness of the Danish version of ThyPRO and comparison with the Perceived Deficits Questionnaire. Value Health, 15(3), 528-534.
Buka referensi publikasiDisalin.